Conduit Pharmaceuticals Inc
CDTTW0.007USD
+0.002+34.55%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Conduit Pharmaceuticals Inc Company
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
Conduit Pharmaceuticals Inc Info
Ticker SymbolCDTTW
Company nameCDT Equity Inc
IPO dateFeb 03, 2022
CEODr. Andrew Regan
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address4851 Tamiami Trail North
CityNAPLES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code34103
Phone16464919132
Websitehttps://www.cdtequity.com/
Ticker SymbolCDTTW
IPO dateFeb 03, 2022
CEODr. Andrew Regan
Company Executives of Conduit Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
--
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
--
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
37
6.77M
0.00%
-2.55M
2025Q3
39
6.77M
0.00%
+530.08K
2025Q2
40
6.24M
0.00%
+456.12K
2025Q1
39
5.78M
0.00%
-3.29M
2024Q4
38
8.01M
0.00%
-1.10M
2024Q3
41
9.11M
0.00%
+282.85K
2024Q2
40
8.83M
0.00%
+22.83K
2024Q1
40
8.80M
0.00%
-1.63M
2023Q4
40
8.69M
0.00%
-902.56K
2023Q3
40
9.59M
0.00%
+207.31K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Two Sigma Investments, LP
14.26K
0%
+2.01K
+16.44%
Sep 30, 2025
Clear Street Group Inc
534.56K
0%
+534.56K
--
Sep 30, 2025
TD Securities, Inc.
755.49K
0%
-300.00
-0.04%
Sep 30, 2025
AQR Arbitrage, LLC
3.68K
0%
-725.00
-16.45%
Sep 30, 2025
Voya Investments, LLC
51.47K
0%
--
--
Oct 31, 2025
Susquehanna International Group, LLP
108.09K
0%
+108.09K
--
Sep 30, 2025
Polar Asset Management Partners Inc.
950.00K
0%
--
--
Sep 30, 2025
Saba Capital Management, L.P.
765.00K
0%
--
--
Sep 30, 2025
MMCAP Asset Management
700.00K
0%
--
--
Sep 30, 2025
Clear Street LLC
534.93K
0%
+125.00K
+30.49%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Conduit Pharmaceuticals Inc?
The top five shareholders of Conduit Pharmaceuticals Inc are:
Two Sigma Investments, LP holds 14.26K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 534.56K shares, accounting for 0.00% of the total shares.
TD Securities, Inc. holds 755.49K shares, accounting for 0.00% of the total shares.
AQR Arbitrage, LLC holds 3.68K shares, accounting for 0.00% of the total shares.
Voya Investments, LLC holds 51.47K shares, accounting for 0.00% of the total shares.
Two Sigma Investments, LP holds 14.26K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 534.56K shares, accounting for 0.00% of the total shares.
TD Securities, Inc. holds 755.49K shares, accounting for 0.00% of the total shares.
AQR Arbitrage, LLC holds 3.68K shares, accounting for 0.00% of the total shares.
Voya Investments, LLC holds 51.47K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Conduit Pharmaceuticals Inc?
The top three shareholder types of Conduit Pharmaceuticals Inc are:
Other
Other
How many institutions hold shares of Conduit Pharmaceuticals Inc (CDTTW)?
As of 2025Q4, 37 institutions hold shares of Conduit Pharmaceuticals Inc, with a combined market value of approximately 6.77M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Conduit Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Conduit Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
